Sana Biotechnology. has filed a patent for engineered cells with genetic modifications for allogeneic cell therapy. The cells, including hypoimmunogenic primary cells, aim to improve the effectiveness of cell therapy. GlobalData’s report on Sana Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sana Biotechnology, Viral vectors was a key innovation area identified from patents. Sana Biotechnology's grant share as of January 2024 was 2%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered hypoimmunogenic cells for allogeneic cell therapy
A patent application (Publication Number: US20240010988A1) describes a method for modifying primary islet cells. The method involves dissociating primary islet clusters into a suspension of primary islet cells, contacting them with specific reagents such as a gene editing system or an agent with an exogenous polynucleotide, and incubating the cells to produce modified islet cells. These modified cells are then re-clustered into modified primary islet cell clusters. Subsequent steps involve further modification of the cells with additional reagents, incubation, and re-clustering into second modified primary islet cell clusters. The method also includes selecting islet cells with modified gene expression, incubating them under specific conditions, and integrating exogenous polynucleotides into the cells.
The method outlined in the patent application offers a detailed process for modifying primary islet cells, potentially for therapeutic purposes in treating conditions like diabetes. By utilizing gene editing systems and specific reagents, the method aims to produce modified islet cells with altered gene expression profiles. The incorporation of tolerogenic factors and the re-clustering of modified cells into clusters are key aspects of the method. The application also mentions the use of specific proteins and nucleic acids for disrupting target genes and reducing cell surface expression of certain molecules. Overall, the method provides a comprehensive approach to engineering primary islet cells, potentially leading to advancements in diabetes treatment and other related medical applications.
To know more about GlobalData’s detailed insights on Sana Biotechnology, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
